Natixis Partners advised the shareholders of Havea Group in the sale of a majority stake of its capital to BC Partners and PSP Investments

Havea is one of the European leaders in natural healthcare, centered on 5 strong strategic brands: Aragan, Biolane, Densmore, Dermovitamina and Vitavea. The Group and its brands help consumers and patients prevent and treat common health issues with premium natural health products. Under the leadership of its CEO, Nicolas Brodetsky, and with the active support of 3i and Cathay since 2017, Havea has undergone a major transformation, doubling in size to reach €212 million revenues in 2021. During this period, Havea has posted double-digit organic growth, significantly outpacing the market by combining a targeted marketing strategy with a scientific and medical approach tailored to each brand, its patients and consumers. In addition, the Group has completed 5 acquisitions in 5 years, significantly strengthening its presence in several European countries. With the help of BC Partners and PSP Investments, Havea's objective is to become the undisputed European leader, notably by acquiring complementary companies while continuing to invest in its digitalization.